Turning Point Brands (TPB): Results – 2025

Share on twitter
Share on email
Share on whatsapp
Share on linkedin

March 2026: Turning Point Brands Accelerates Modern Oral Expansion, Steps Up Investment in 2026

Turning Point Brands (TPB) reported strong fourth quarter and full-year 2025 results, driven by rapid growth in its Modern Oral nicotine pouch portfolio, while signaling increased investment and near-term margin variability as it scales distribution and marketing in 2026.

Fourth quarter net sales increased 29% year-over-year to $121 million, with Adjusted EBITDA rising 14% to $30 million. Modern Oral net revenue reached $41.3 million in the quarter, up 266% year-over-year, and now accounts for 34% of consolidated net sales, compared to 12% a year ago. Gross margin was stable at 55.9%. The company ended the year with $222.8 million in cash and generated $19.2 million in free cash flow in Q4.

Within segments, Stoker’s net sales increased 70% to $81 million, reflecting both 9% growth in legacy brands and the sharp increase in Modern Oral revenue. Zig-Zag net sales declined 13% to $40 million, in line with expectations, as the company prioritized investment and focus on nicotine pouches. Stoker’s segment gross margin was affected by elevated tariff rates in the quarter, which pressured gross margins despite an EBITDA add-back adjustment.

TPB Management emphasized accelerating distribution gains for its white pouch brands, FRE and ALP. FRE continued to expand across large regional and national convenience chains, while ALP, initially planned as a direct-to-consumer-only brand through 2025, has begun appearing in brick-and-mortar retail tests ahead of schedule. A broader retail rollout for ALP is planned for the second quarter of 2026. The company indicated that ALP’s early retail performance has exceeded expectations and that store count growth could mirror FRE’s early expansion trajectory.

To support this growth, Turning Point Brands is making significant strategic investments in sales and marketing. Initiatives include expanding and nearly doubling the sales force ahead of schedule, improving online presence, increasing trade and chain account investments, pursuing brand partnerships, and enhancing merchandising capabilities. The company is also investing in U.S. manufacturing capacity for white pouches, with initial production lines expected to be qualified in the coming months. Domestic production is expected to supplement existing international supply, with potential margin benefits emerging toward the end of 2026 as inventory flows through the P&L.

Given the front-loaded nature of these investments, TPB management cautioned that EBITDA beyond the first quarter of 2026 is difficult to forecast with precision. The company expects first quarter 2026 Adjusted EBITDA in a range of $24 million to $27 million, reflecting stepped-up sales and marketing spending and preparation for ALP’s retail launch. Investment levels are expected to be “lumpy” throughout the year, depending on perceived high-ROI opportunities.

For 2026, the company initiated Modern Oral gross revenue guidance of $220 million to $240 million and net revenue guidance of $180 million to $190 million. It is worthwhile to underline the gross-to-net revenue difference of $45 million or roughly 20% (i.e. high cost of expanding the retail presence for a small player). CAPEX is budgeted at $4 million to $5 million, excluding Modern Oral projects, with an additional $3 million to $5 million planned to support PMTA-related activities.

TPB Management reiterated its long-term view that the U.S. nicotine pouch category could approach or exceed $10 billion in manufacturer revenue by the end of the decade and that the market will likely consolidate around five to six leading brands. Turning Point Brands is targeting a double-digit market share over time and positioning FRE and ALP as leading challenger brands.

On risk factors, TPB Management highlighted two key areas. First, ongoing and potentially increasing state-level taxes on nicotine pouches could influence pricing and promotional strategies, although the company views tax changes as a category-wide dynamic that does not disproportionately disadvantage individual players. Second, elevated tariff rates have already impacted Stoker’s segment gross margins, underscoring exposure to cost volatility.

Overall, TPB expressed confidence in the momentum exiting 2025, while acknowledging that 2026 will be characterized by elevated investment, near-term earnings variability, and execution risk as the company aggressively scales its Modern Oral platform.

March 2, 2026: Q4 2025 & FY25 Results

– Net sales: up +29.2% to $121 million in Q4 2025; up +28.4% to $463.1 million in FY25

– Stoker’s (67% of total sales): up +69.5% to $81 million in Q4 2025, driven by triple-digit growth in modern oral sales and single-digit growth in legacy products. Up +69.1% to to $284.6 million in FY25

– Zig-Zag (67% of total sales): down -12.8% to $40 million in Q4 2025, driven by the planned wind-down of the Clipper business and allocation of sales and marketing resources to white pouch. Low-double-digit decline in the U.S. partially offset by low-double-digit growth in Canadian sales. Down -7.2% to $178.5 million in FY25

– Modern Oral: up +266% to $41.3 million in Q4 2025, accounting for 34% of total net sales (vs. 12% in Q4 2024)

– SG&A expenses increased 38.2% from the prior year and 7.2% sequentially to $47.7 million in Q4 2025, including $1.1 million FDA PMTA-related expenses (vs. $0.5 million in Q4 2024), modern oral-related sales and marketing investments and increased outbound freight costs

– Gross Profit: up +29.1% to $67.7 million in Q4 2025; up +31.1% to $264.3 million in FY25

– Net Income: up +239.8% to $8.2 million in Q4 2025; up +46.1% to $58.2 million in FY25

– Adjusted EBITDA: up +14.4% to $30 million in Q4 2025; up +14.4% to $119.5 million in FY25

– Reported/Adjusted EPS: $0.42/$0.95 in Q4 2025 vs. $0.13/$0.98 in Q4 2024; $3.11/$3.96 in FY25 vs. $2.14/$3.49 in FY24

– Liquidity (as of year-end 2025): $222.8 million cash, $77.2 million net debt. Total liquidity of $290.1 million, comprised of cash and $68.1 million of asset backed revolving credit facility capacity

FY 2026 Guidance:

– Modern Oral gross revenue: $220-$240 million and net revenue of $180-$190 million. Well positioned to achieve double-digit share of the category over time

– Q1 2026 Adjusted EBITDA: $24-$27 million, inclusive of investment in Modern Oral sales, marketing, and trade promotions.

Download the Press Release: TPB Q4 2025 & FY25 Results

November 5, 2025: Q3 2025 Results

– Net Sales: up +31.2% to $119 million

– Stoker’s (63% of net sales): Net sales up +80.8% to $74.8 million, driven by FRE and ALP nicotine pouches; mid-single-digit growth in MST; low single-digit growth in looseleaf. Gross profit up +95.2% to $45 million; Gross margin up +440bps to 60.2%

– Modern Oral Net Sales: up +628% $36.7 million (- representing 31% of total sales), up +22% on a sequential basis. First U.S. white pouch production lines to be qualified in H1 2026

– Zig-Zag (37% of net sales): Net sales down -10.5% year-on-year and -6.1% sequentially; excluding the wind-down of our Clipper business, sales up mid-single-digit sequentially; Gross profit down -7.1% to $25.4 million; Gross margin up +210 basis points to 57.5%

– Gross Profit: up +39.7% to $70.4 million; Gross profit margin: +3.6pp to 59.2%

– Adjusted EBITDA: up +17.2% to $21.1 million; EBITDA margin: -2.1pp to 17.7%

– Net income up +70.3% to $21.1 million; Adjusted net Income: up +18.3% to $19.6 million

– EPS: $1.13 reported and $1.27 adjusted, up +66% and +40%, respectively, compared to $0.68 and $0.91 in Q3 2024

– Raised $97.5 million of net proceeds at an average price of $98.59 per share; capital to be deployed to accelerate growth of Modern Oral

– SG&A: up +50.5% to $44.5 million (up +10.5% sequentially), primarily driven by nicotine pouch-related commercial investments and increased outbound freight costs; $0.5 million of FDA PMTA-related expenses for Modern Oral products (vs. $1.2 million in Q3 2024); $0.8 million of transaction-related costs (vs. $0.9 million in Q3 2024)

– Gross debt: $300 million. Net debt: $98.8 million. Liquidity: $267.8 million ($201.2 million in cash and $66.6 million of availability under asset backed revolving credit facility)

– Share buyback and sales authorization limit updated to $200 million (currently, no plans to transact)

– FY25 Guidance: Adjusted EBITDA of $115-120 million (before: $110-114 million; mid-point: +4.9%); Modern Oral sales: $125-130 million (before: $100-110 million; mid-point: +21.4%)

Our take: TPB’s Q3 2025 results are spectacular, driven by +628% growth in FRE and ALP nicotine pouch sales. Moreover, sales trend in looseleaf and Zig-Zag portfolio, ex-Clipper, turned positive in year-on-year and sequential basis, respectively. Stabilization in the traditional categories is noteworthy and important not to drag down the explosive growth in nicotine pouches. SG&A is up +50.5% year-on-year, mostly driven by the commercial investments made in nicotine pouches. As a result, FY25 EBITDA guidance increase (+$5.5 million) is small compared to a major uplift in nicotine pouch sales forecast (+$22.5 million). Nevertheless, TPB is set to deliver $3.4-3.5 FY25 EPS (+60% growth year-on-year basis).

It is undeniable that TPB broke out of its ailing core OTP business thanks to the nicotine pouches and transformed its financial delivery into one of a fast-growth company – albeit certain risk in the sustainability of growth in the long-term due to the strict regulatory environment in the U.S (for the players that are bound to play by the rules). Trading at an all-time high, above $100 and around 30x P/E, TPB sets an example for the power of the transformation in the tobacco industry.

August 6, 2025: Q2 2025 Results

– Net Sales: up+25.1% to $116.6 million

– Stoker’s (60% of net sales): Net sales up +62.9% to $69.6 million, driven by FRE and ALP nicotine pouches; mid-single-digit growth in MST; low single-digit declines in looseleaf; Volume up +48.3% while price / product mix up + 14.5%. Gross profit up +85% to $43.5 million (up +27.8% sequentially); Gross margin up +750bps to 62.5% (up +500 bps sequentially)

– Modern Oral Net Sales: up +651% $30.1 million (- representing 26% of total sales), up +35% on a sequential basis

– Zig-Zag (40% of net sales): Net sales down -6.9%, flat sequentially; Gross profit down -14.0% to $23.1 million; Gross margin down -410 basis points to 49.1%, driven by product mix.

– Gross Profit: up +32.2% to $66.6 million; Adjusted EBITDA: up +14.8% to $30.5 million; Net Income: up +11.3% to $14.5 million; Adjusted Net Income: up +4.5% to $18.0 million

– EPS: $0.79 reported and $0.98 adjusted, up +16% and +10%, respectively, compared to $0.68 and $0.89 in Q2 2024

– SG&A: $40.3 million (vs. $29.2 million in Q2 2024), primarily driven by white pouch-related SG&A, increased outbound freight and sales and marketing investments

– Gross debt: $300 million. Net debt: $190.1 million. Liquidity: $176.4 million ($109.9 million in cash and $66.5 million of availability under asset backed revolving credit facility)

– FY25 Guidance: Adjusted EBITDA of $110-114 million (before: $108-113 million; mid-point: +1.4%); Modern Oral sales: $100-110 million (before: $80-95 million; mid-point: +20%)

Our take: TPB’s Q2 2025 results are spectacular, driven by +651% growth in FRE and ALP nicotine pouch sales. However, with very high expectations heading into the earnings release, the results did not come in without any concerns. The structural decline in Zig-Zag portfolio and looseleaf is ongoing. Nicotine pouch growth comes with a major increase in SG&A (+38% year-on-year; mostly related to the regulatory expenses and marketing investments for nicotine pouches). As a result, FY25 EBITDA guidance increase (+1.4%) is minimal despite a major uplift in nicotine pouch sales forecast (+20%). When shares are trading at an all-time high around 25x P/E, some investors may tend to focus on the impurities – rather than a great growth story. In any case, it is undeniable that TPB broke out of its ailing core OTP business thanks to the nicotine pouches and transformed its financial delivery into one of a fast-growth company – albeit certain risk in the sustainability of growth in the long-term due to the strict regulatory environment in the U.S (for the players that are bound to play by the rules).

May 7, 2025: Q1 2025 Results

– Net Sales: up +28.1% to $106.4 million; Stoker’s net sales (including nicotine pouches) is up +62.7% while Zig-Zag net sales up only +1.2%

– Modern Oral Tobacco (“FRE & ALP nicotine pouches”): sales up nearly 10x versus Q1 2024, nearly 2x versus Q4 2024 to $22.3 million (- already 21% of the total sales)

– SG&A expenses: up +25.1% to $36.4 million, primarily driven by ALP-related SG&A, PMTA-related expenses for modern oral products and transaction costs

– Adjusted EBITDA: up +12.0% to $27.7 million

– Gross profit: up +23.3% to $59.6 million; Net income: up +19.8% to $14.4 million; Adjusted net income: up +8.0% to $16.7 million

– Diluted EPS: $0.79 ($0.63); Adjusted Diluted EPS: $0.91 ($0.80)

– FY25 Guidance: Adjusted EBITDA guidance of $108-113 million (re-iterated). Nicotine pouch sales guidance increased from a range of $60-80 million to $80-95 million (i.e. 25% increase in midpoint)

– Gross debt: $300 million. Net debt: $200.4 million. Total liquidity: $161.8 million ($99.6 million cash and $62.2 million revolving credit facility)



Tags:

Call Request:
Reports

We will reach out to you within 24 hours to discuss your request. Please note that we only respond to requests with a valid business e-mail address
Disclaimer: The content in our Market Pulse section is/shall not be construed as investment advice. It is for informative purposes only and does not take into account the individual needs, investment objectives and specific financial circumstances. Any action taken upon the information in our Market Pulse section is strictly at the reader’s own risk. We assume no responsibility or liability for the actions taken. Moreover, we also assume no responsibility or liability for any errors or omissions in our content – which is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness even if we only depend on the infromation sources that are believed to be accurate.

Consultation
Session Request

We will reach out to you within 24 hours to discuss your request. Please note that we only respond to requests with a valid business e-mail address